Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.

Autor: Mittal K; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Cooper GW; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Lee BP; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Su Y; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Skinner KT; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Shim J; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Jonus HC; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Kim WJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Doshi M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Almanza D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kynnap BD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Christie AL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Yang X; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Cowley GS; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Leeper BA; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Morton CL; Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA., Dwivedi B; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Lawrence T; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Rupji M; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Keskula P; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Meyer S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Clinton CM; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bhasin M; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Crompton BD; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tseng YY; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Boehm JS; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ligon KL; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Root DE; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Murphy AJ; Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Merck & Co., Rahway, NJ, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Spangle JM; Winship Cancer Institute, Emory University, Atlanta, GA, USA.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA., Rivera MN; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Mullen EA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stegmaier K; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Goldsmith KC; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. william_hahn@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. william_hahn@dfci.harvard.edu., Hong AL; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. andrew.hong2@emory.edu.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. andrew.hong2@emory.edu.; Winship Cancer Institute, Emory University, Atlanta, GA, USA. andrew.hong2@emory.edu.

Publikováno v: Communications biology [Commun Biol] 2024 Apr 08; Vol. 7 (1), pp. 426. Date of Electronic Publication: 2024 Apr 08.

The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma.

Autor: Durall RT; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Huang J; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Wojenski L; BasePair, New York, New York., Huang Y; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Leeper BA; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Nash JO; Program in Genetics and Genome Biology, The Hospital for Sick Children (SickKids), University of Toronto, Toronto, Ontario, Canada.; Laboratory of Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada., Ballester PL; Program in Genetics and Genome Biology, The Hospital for Sick Children (SickKids), University of Toronto, Toronto, Ontario, Canada., Davidson S; Program in Genetics and Genome Biology, The Hospital for Sick Children (SickKids), University of Toronto, Toronto, Ontario, Canada., Shlien A; Program in Genetics and Genome Biology, The Hospital for Sick Children (SickKids), University of Toronto, Toronto, Ontario, Canada.; Laboratory of Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada., Sotirakis E; genOway, Lyon, France., Bertaux F; genOway, Lyon, France., Dubus V; genOway, Lyon, France., Luo J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Keskin DB; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts., Eagen KP; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.; Center for Precision Environmental Health, Baylor College of Medicine, Houston, Texas.; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, Texas.; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., French CA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Publikováno v: Cancer research [Cancer Res] 2023 Dec 01; Vol. 83 (23), pp. 3846-3860.

EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes.

Autor: Huang Y; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Durall RT; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Luong NM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Hertzler HJ; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Huang J; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Leeper BA; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Persky NS; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Root DE; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Anekal PV; MicRoN, Department of Microbiology, Harvard Medical School, Boston, MA, USA., Montero Llopis PDLM; MicRoN, Department of Microbiology, Harvard Medical School, Boston, MA, USA., David CN; NanoString Technologies, Inc., Seattle, WA, USA., Kutok JL; Epizyme Inc., Cambridge, MA, USA., Raimondi A; Epizyme Inc., Cambridge, MA, USA., Saluja K; Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, TX, USA., Luo J; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Zahnow CA; Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Adane B; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA., Hawkins CE; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., Ponne C; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., Le Q; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., Shapiro GI; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Lemieux ME; Bioinfo, Plantagenet, ON, Canada., Eagen KP; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., French CA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Aug 16. Date of Electronic Publication: 2023 Aug 16.

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.

Autor: To C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Beyett TS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Jang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; College of Pharmacy, Korea University, Sejong, Korea., Feng WW; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Bahcall M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Haikala HM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Shin BH; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Heppner DE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Chemistry, University at Buffalo, Buffalo, NY, USA., Rana JK; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Leeper BA; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Poitras MJ; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Kobayashi Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan., Wahid K; Institute of Biomedicine, MediCity Research Laboratories, University of Turku, Turku, Finland., Kurppa KJ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Institute of Biomedicine, MediCity Research Laboratories, University of Turku, Turku, Finland., Gero TW; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Cameron MD; Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA., Ogino A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Mushajiang M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Xu C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Zhang Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Scott DA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. DavidA_Scott@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. DavidA_Scott@dfci.harvard.edu., Eck MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. michael_eck@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. michael_eck@dfci.harvard.edu., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Medicinal Chemistry and Department of Chemistry and Systems Biology, Stanford University, Stanford, CA, USA. nathanael_gray@dfci.harvard.edu., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. pasi_janne@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. pasi_janne@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. pasi_janne@dfci.harvard.edu.

Publikováno v: Nature cancer [Nat Cancer] 2022 Apr; Vol. 3 (4), pp. 402-417. Date of Electronic Publication: 2022 Apr 14.